trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['gastric', 't-dxd', 'nsclc', 'sclc', 'breast']
t-dxd was recently approved for use against #her2-low breast cancer and her2-mutant nsclc. msk s geoffrey ku &amp; colleagues present evidence at #esmo22 of substantial clinical benefit and a tolerable safety profile in her2+ metastatic #gastriccancer. 
The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences